Journal Article

Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial

Baraliakos, Xenofon, Landewé, Robert B M, Bauer, Lars, Maksymowych, Walter P, Hoepken, Bengt, Braun, Juergen, Hermann, Kay-Geert A, Machado, Pedro M, Davies, Owen R, Nurminen, Tommi, de Peyrecave, Natasha, van der Heijde, Désirée

2018

Overview

ObjectivesTo report 4-year imaging outcomes in the RAPID-axSpA (NCT01087762) study of patients with ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA), treated with certolizumab pegol (CZP).MethodsThis phase III, randomised trial was placebo-controlled and double-blind to week 24, dose-blind to week 48 and open-label to week 204. Patients fulfilling the Assessment of Spondyloarthritis International Society (ASAS) axSpA criteria with active disease were stratified (AS/nr-axSpA) according to the modified New York (mNY) criteria at randomisation. Spinal radiographs were assessed using the modified Stoke Ankylosing Spondylitis Spine Score (mSASSS). MRI inflammation used the Spondyloarthritis Research Consortium of Canada (SPARCC) score for sacroiliac joints (SIJ) and the Berlin spinal score (remission defined as SPARCC <2 and Berlin ≤2, respectively).ResultsMRI improvements from baseline (BL) to week 12 were maintained to week 204 (SPARCC BL: AS=8.5, nr-axSpA=7.5; SPARCC week 204: AS=1.3, nr-axSpA=2.4; Berlin BL: AS=7.4, nr-axSpA=4.4; Berlin week 204: AS=2.6, nr-axSpA=1.9). 66.7% of patients with AS and 69.6% of patients with nr-axSpA with BL SPARCC scores ≥2, and 65.4% of patients with AS and 57.3% of patients with nr-axSpA with BL Berlin score >2, achieved remission at week 204. Mean mSASSS change in AS from BL to week 204 was 0.98 (95% CI 0.34, 1.63); 0.67 (95% CI 0.21,1.13) from BL to week 96; and 0.31 (95% CI 0.02,0.60) from week 96 to week 204. Corresponding nr-axSpA changes were 0.06 (95% CI −0.17,0.28), –0.01 (95% CI −0.19,0.17) and 0.07 (95% CI −0.07,0.20). 4.5% of patients with nr-axSpA fulfilled the mNY criteria at week 204, while 4.3% of patients with AS no longer did so.ConclusionsIn patients with CZP-treated axSpA, rapid decreases in spinal and SIJ MRI inflammation were maintained to week 204. Overall, 4-year spinal progression was low, with less progression during years 2–4 than 0–2. Radiographic SIJ grading changes demonstrated limited progression.Trial registration number NCT01087762; Post-results.

• Publisher: Elsevier Limited,BMJ Publishing Group
• Subject: Adult / Ankylosing spondylitis / Antirheumatic Agents - therapeutic use / Arthritis / Certolizumab Pegol - therapeutic use / Clinical and Epidemiological Research / Disease Progression / Double-Blind Method / Female / Humans / Induction Chemotherapy / Inflammation / Inflammation - diagnostic imaging / Inflammatory diseases / Joint diseases / Magnetic resonance imaging / Magnetic Resonance Imaging - methods / Male / Market shares / Middle Aged / Monoclonal antibodies / Patients / Radiography / Reading promotion / Remission / Rheumatic diseases / Rheumatology / Sacroiliac Joint - diagnostic imaging / Severity of Illness Index / Spine / Spine - diagnostic imaging / Spondylarthritis - diagnostic imaging / Spondylarthritis - drug therapy / Spondylarthritis - pathology / Spondylitis / Studies / TNF inhibitors / Treatment Outcome / Tumor necrosis factor-TNF / Tumor necrosis factor-α / X-rays